Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy?
Poseida Therapeutics is aiming to find that out in the very near future.
The San Diego-based biotech filed their S-1 on a busy Friday, just ahead of the big JPMorgan confab that gets underway Monday morning in San Francisco. In it, they lay out an early snapshot on Phase I data for P-BCMA-101 targeting multiple myeloma — a familiar target in the CAR-T world these days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.